Development of PARP and immune-checkpoint inhibitor combinations

165Citations
Citations of this article
131Readers
Mendeley users who have this article in their library.

Abstract

PARP inhibitors drive increased DNA damage, particularly in tumors with existing defects in DNA repair. This damage not only promotes immune priming through a range of molecular mechanisms, but also leads to adaptive upregulation of programmed death ligand 1 (PD-L1) expression. In this context, PARP inhibition and programmed cell death 1 (PD-1)/PD-L1–targeting antibodies represent a rationale combination. In this review, we detail the basic and translational science underpinning this promising new combination, summarize available clinical data, and discuss the key questions that remain to be addressed during future development.

Cite

CITATION STYLE

APA

Stewart, R. A., Pilie, P. G., & Yap, T. A. (2018, December 15). Development of PARP and immune-checkpoint inhibitor combinations. Cancer Research. American Association for Cancer Research Inc. https://doi.org/10.1158/0008-5472.CAN-18-2652

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free